Global Drug Eluting Balloons (DEB) Market Size By Type (Peripheral DEBs, Coronary DEBs), By Application (Catheterization Laboratory, Hospital), By Region, And Segment Forecasts, 2023 to 2032

lobal Drug Eluting Balloons (DEB) Market Report Description

The Global Drug Eluting Balloons (DEB) Market was valued at USD 1.8 billion in 2023 and is projected to reach USD 3.4 billion by 2031, growing at a CAGR of 8.2% during the forecast period 2023–2031.

Drug eluting balloons are a rapidly growing segment within interventional cardiology, designed to deliver antiproliferative drugs directly to the arterial wall during angioplasty procedures. Unlike drug-eluting stents (DES), DEBs leave no permanent implants, reducing risks of restenosis and long-term complications.

The market growth is fueled by rising prevalence of cardiovascular diseases, increasing demand for minimally invasive procedures, technological advancements in drug coatings, and expanding applications beyond coronary artery disease to include peripheral artery disease (PAD) treatment.

Drivers

Rising Prevalence of Cardiovascular Diseases

Cardiovascular diseases remain the leading cause of death worldwide, driving demand for advanced treatment options like DEBs that offer superior outcomes compared to traditional angioplasty.

Preference for Minimally Invasive Procedures

DEBs allow clinicians to treat restenosis without leaving metallic implants, reducing long-term complications, hospital stays, and improving patient recovery times.

Technological Advancements in Drug-Coating

Innovations in balloon coating technologies, such as controlled drug release mechanisms and polymer-free formulations, are improving efficacy and reducing adverse events.

Restraints

High Cost of DEB Procedures

Compared to plain old balloon angioplasty (POBA), DEBs remain relatively expensive, limiting adoption in cost-sensitive regions.

Stringent Regulatory Approvals

Regulatory hurdles and the need for extensive clinical data to demonstrate safety and efficacy delay product launches and market penetration.

Opportunity

Growing Applications in Peripheral Artery Disease (PAD)

DEBs are increasingly being used to treat PAD, particularly in femoropopliteal and below-the-knee lesions, presenting a significant growth opportunity.

Emerging Markets in Asia-Pacific and Latin America

Rising healthcare expenditure, better access to advanced cardiology interventions, and a growing patient pool in emerging economies create untapped market potential.

Market by System Type Insights

Coronary Drug Eluting Balloons held the largest market share in 2023, widely used for treating in-stent restenosis and small vessel disease.

Peripheral Drug Eluting Balloons are expected to record the highest growth during the forecast period due to the increasing incidence of peripheral artery disease and the preference for non-stent solutions.

Market by End-use Insights

Hospitals & Cardiac Centers accounted for over 60% of the market share in 2023, as most angioplasty procedures are performed in specialized medical facilities with advanced catheterization labs.

Ambulatory Surgical Centers (ASCs) are expected to grow rapidly due to the shift toward outpatient procedures for cost-effectiveness and convenience.

Market by Regional Insights

Europe dominated the market in 2023, supported by strong reimbursement policies, high awareness, and early adoption of DEB technology.

North America follows closely, driven by advanced healthcare infrastructure and rising cases of restenosis.

Asia-Pacific is projected to grow at the fastest CAGR due to increasing cardiovascular disease prevalence, improving healthcare access, and a growing aging population.

Competitive Scenario

Key players in the global DEB market include Medtronic plc, B. Braun Melsungen AG, Boston Scientific Corporation, BIOTRONIK SE & Co. KG, Concept Medical, Terumo Corporation, Abbott Laboratories, and Philips Healthcare.

In 2024, Medtronic launched its next-generation paclitaxel-coated balloon with improved drug transfer efficiency.

In 2023, Boston Scientific received expanded FDA approval for its DEB platform in treating complex coronary lesions.

BIOTRONIK continued to expand its portfolio with clinical trials supporting use in below-the-knee PAD interventions.

Scope of Work – Global Drug Eluting Balloons (DEB) Market

Key Market Developments

2024: Medtronic launched a polymer-free DEB with enhanced drug delivery for both coronary and peripheral applications.

2023: BIOTRONIK completed a pivotal clinical trial demonstrating superior outcomes in PAD patients using its latest DEB platform.

2023: Concept Medical expanded its manufacturing capacity in Asia to meet growing regional demand.

FAQs

What is the current market size of the Global Drug Eluting Balloons (DEB) Market?

The market was valued at USD 1.8 billion in 2023.

What is the major growth driver of the Global Drug Eluting Balloons (DEB) Market?

The key driver is the increasing prevalence of cardiovascular and peripheral artery diseases, coupled with the preference for minimally invasive treatments.

Which is the largest region during the forecast period in the Global Drug Eluting Balloons (DEB) Market?

Europe remains the leading market due to early technology adoption and favorable reimbursement policies.

Which segment accounted for the largest market share in Global Drug Eluting Balloons (DEB) Market?

Coronary DEBs hold the largest market share in 2023.

Who are the key market players in the Global Drug Eluting Balloons (DEB) Market?

Key players include Medtronic, Boston Scientific, BIOTRONIK, B. Braun, Abbott Laboratories, and Terumo Corporation.

Would you like me to create a professionally formatted PDF report for the Global DEB Market with this structured content? Or should I also add a graphical market trend forecast chart?